Docetaxel - Carboplatin As Second Line Treatment in Patients with Small Cell Lung Cancer
NCT00686985
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Small Cell Lung Cancer
Interventions
DRUG:
Carboplatin, docetaxel
Sponsor
Dr. B. Biesma